Obesity is a major public health problem and substantially increases the risk of type 2 diabetes, hypertension, stroke, cardiovascular, respiratory problems, gall bladder disease, osteoarthritis and sleep apnoea, as well as certain cancers. The prevalence of obesity is rapidly increasing worldwide. However, for individuals weight is regulated within a narrow range. This regulation depends on energy intake (in the form of food) and energy expenditure. Recently, there has been a remarkable increase in our understanding of the homeostatic mechanisms that control food intake and energy homeostasis.
Introduction
An established central dogma for the central nervous system (CNS) regulation of appetite has evolved. There are two key inputs -the brain stem and the arcuate nucleus. The brain stem receives the messages from both the gut neural system directly and from the blood stream through the area postrema. The arcuate nucleus of the hypothalamus (ARC) receives input from the other parts of the brain and also, again, directly from the bloodstream. Within the ARC there are two interconnecting positive and negative collections of neurones (neuropeptide Y (NPY) and agouti-related protein (AgRP), and cocaine and amphetamine-regulated transcript (CART) and pro-opiomelanocortin (POMC), respectively). These project to the paraventricular nucleus (PVN), where regulation of food intake and energy expenditure is controlled by as yet unknown mechanisms. This system is regulated by negative signals from fat tissue (leptin) and gut hormones, and by a positive signal from the stomach (ghrelin). Postprandial anorexia is not obviously explained by either gut distension or by circulating nutriments. Thus, direct signals from the gut appear to be likely and could be mediated either by the gut neural or hormonal systems.
Central control of appetite
POMC is a precursor molecule that modulates energy homeostasis by giving rise to the anorectic peptide amelanocyte stimulating hormone (a-MSH), an agonist at the melanocortin 3 (MC3) and melanocortin 4 (MC4) receptors. POMC has a limited distribution, with only two neuronal populations described: one in the ARC (known as the infundibular nucleus in man) and the other in the nucleus of the tractus solitarus (NTS) [1 • ]. AgRP, however, is the endogenous antagonist of the MC3 and MC4 receptors.
a-MSH exerts a tonic inhibitory control on food intake and energy storage through its actions in the central nervous system (CNS) at MC3 and MC4 receptors. Transgenic animals and humans lacking the POMC gene or with the MC4 mutations are hyperphagic and obese [2 • ,3 • ] with defects in the MC4 receptor gene being linked to severe early-onset obesity in children in particular. In a study of 500 severely obese probands (children and adults) defects in the MC4 gene were found in up to 6% of cases [4 •• ].
NPY is a member of a peptide family consisting of two other hormones, peptide YY (PYY) and pancreatic polypeptide (PP). NPY, PYY and PP share a common hairpin-like three-dimensional structure that has been called the PPfold. There are four functional Y receptors in humans, Y1, Y2, Y4 and Y5, with another receptor present in rodents, the y6. NPY, like AgRP, is a potent orexigenic agent, which both initiates and maintains feeding probably via Y1 and Y5 hypothalamic receptors.
Recent studies show that consumption of high fat diet rapidly down-regulates hypothalamic NPYergic signalling, as well as reducing ARC POMC mRNA [5, 6] . Further investigation has shown decreased hypothalamic NPY levels and outflow from the hypothalamus simultaneously with increased sensitivity to NPY [7 • ].
Transgenic and knockout models are powerful tools for studying the functions of genes. This is especially the case in systems like the NPY family. Y1 and Y5 germline mice knockouts have relatively normal phenotype, but develop late-onset obesity, while Y4 show decreased food intake and reduced body weight [8 • ]. Current work has been looking at a variety of double-knockouts and conditional knockouts. To date, this research strongly indicates that NPY acts as a downstream mediator of leptin. For a detailed review of the subject refer to [8 • ].
Leptin appears to exert hypothalamic actions by causing the hyperpolarisation of the NPY/AgRP neurons in the ARC leading to a reduction in the release of g-aminobutyric acid (GABA), thus causing disinhibition of the POMC neurons with which they synapse [9 • ]. In addition, leptin appears to act directly on the POMC system by depolarisation of the ARC POMC neurons, thus increasing their firing rate. This is now thought to represent long-term regulation of energy homeostasis. Short-term regulation of energy homeostasis by gut hormones also is mediated through the ARC. PYY 3-36 acts on Y2 auto-receptors on NPY/AgRP neurons in the ARC that inhibits their firing and thus increases the rate of firing of POMC neurons as described above [10] . Recently, it has been found though that the anorectic effect PYY 3-36 can occur in the absence of MC4 receptors and POMC [11 • ,12 • ], suggesting that PYY 3-36 may also act via different mechanisms. In contrast, the orexigenic effects of ghrelin appear to be mediated by the inhibition of POMC neuronal firing, caused by the action of GABA release from NPY/AgRP neurons [13 • ].
It is also becoming apparent that the brainstem may have important roles in the neuroendocrine regulation of food intake [1 • ]. The brainstem receives input from the vagus nerve, as well as circulating humoral regulators via the area postrema. POMC probably exerts some of its effects on energy homeostasis via the brainstem. Although the brainstem also has neurons with NPY immunoactivity, it has little, if any, AgRP immunoactivity, suggesting that other mechanisms are involved in the activities of POMC neurons here. Recent work suggests that both ghrelin and glucagon-like peptide 1 (GLP-1) can mediate their effects on food intake just through the brainstem, reinforcing the importance of the brainstem in appetite regulation
Peripheral control of appetite: adipostat factors
Adipostat factors, notably leptin and insulin, are recognized as being important in the neuroendocrine control of appetite.
Leptin
Leptin is expressed and secreted by adipocytes in white adipose tissue and circulates in plasma at concentrations proportional to fat mass. Peripheral and CNS administration of leptin to rodents reduces food intake and body weight and increases energy expenditure [18] . Within the CNS, leptin's neuroendocrinological actions are mediated by the hypothalamus. Endogenous, peripherally secreted leptin enters the CNS either by active uptake or simple diffusion in areas outside of the blood brain barrier. Leptin therefore acts as the afferent limb of a body fat reg-
Recently, Pinto et al. have published studies that suggest that besides regulating neuronal activity and neuropeptide release and expression, leptin also affects neuronal plasticity in the hypothalamic neurons critical in the regulation of body weight homeostasis [20 •• ]. Bouret et al.
[21 •• ] meanwhile have shown that leptin acts as a neurotrophic growth factor during the development of the hypothalamus. Leptin seems to be required for the normal innervation of targets, in particular the PVN, by the ARC POMC and NPY/AgRP neurons. These latter findings are consistent with the hypothesis that the nutrition status at critical periods of hypothalamic development can have potentially irreversible effects into adulthood, thus providing a physiologic basis for previous epidemiological findings [22] . Both of these studies also may provide a neuroanatomical and functional framework for a hypothalamic body weight set point [23 • ].
Insulin
Insulin may play a similar role to leptin as an adiposity signal and like leptin, meets criteria for being an adiposity signal; basal circulating levels of insulin correlate with body adiposity level, insulin is transported across the blood-brain barrier, causing expression of signal-transducing molecules in brain areas that control energy homeostasis and the ability to reduce food intake on central administration. Hypothalamic defects in insulin signalling, like leptin cause increased food intake and body adiposity [24 • ]. Recent research even suggests that hypothalamic insulin and leptin signalling converge upon a single intracellular signal transduction pathway [24 • ].
Peripheral control of appetite: gut hormones
Gut hormones have unexpectedly been found to be important in the regulation of appetite before and after every meal.
Ghrelin
Ghrelin is the only peripherally active appetite-stimulating hormone so far discovered and is predominantly secreted by the stomach. Ghrelin potently stimulates food intake and growth hormone secretion following peripheral administration in man and rats [25] [26] [27] . Plasma ghrelin levels are inversely correlated with body weight and fall following weight loss in humans [28 • ]. The ghrelin receptor (GHS-R) is highly expressed in the hypothalamus, including the ARC, but also found in the brain stem, pituitary, gastrointestinal tract, adipose tissue and other peripheral tissues. Ghrelin has previously been implicated in meal initiation [28 • ] though recent work has shown that circulating ghrelin levels do not predict intermeal interval in humans Recently, ghrelin has been found to have a unique distribution in the brain encompassing the internuclear space between the ARC, ventromedial (VMH), dorsomedial (DMH) and PVH, and that ghrelin containing neurons forms synapses with NPY/AgRP and POMC neurons of the ARC [32 •• ]. The presence of ghrelin containing neurons could explain how central ghrelin administration exerts its effects as evidence suggests that peripheral ghrelin appears to work with intact vagus only [33] . It is interesting to note that the patterns of neuronal activation following peripheral and central ghrelin administration differ [30, 34] .
Chronic peripheral ghrelin administration causes hyperphagia and obesity in rats [25, 26] . Although there is little change in body weight or food intake in ghrelin or GHS-R knockout animal models, this may be due to compensatory developmental changes in other appetite regulatory systems [35 • ,36 • ,37 • ].
Peptide YY and pancreatic polypeptide
Pancreatic polypeptide (PP) and peptide YY (PYY) are anorectic gut hormones belonging to the PP-fold peptide family.
Full-length PYY binds with high affinity to all Y receptors. However, most PYY found stored in cells and present in circulation is in the form PYY 3-36 , a truncated 34 amino acid peptide generated by the cleavage of two amino acids from the N terminus. PYY 3-36 has high affinity for the Y2, and a lesser affinity for Y1 and Y5 receptors. Peripheral administration of PYY 3-36 at doses mimicking post-prandial levels activates neurons in the ARC and markedly inhibits food intake in rodents and man. Food intake and body weight are reduced in rodents chronically treated with peripheral PYY 3-36 [10] . The effects of PYY 3-36 on food intake have been confirmed by other groups [11 • ,12 • , 38 • ,39 • ,40 • ,41 • ,42 • ], PYY inhibits appetite through inhibition of the NPY appetite stimulating neurones in the ARC. Stress inhibition of food intake is also thought to act through this system. Thus, animals with stress inhibition of food intake do not respond to PYY as they are already fully inhibited. Failure to properly control for stress has led some to wrongly claim that PYY doesn't inhibit food intake in the rat [43] . In rodents, at least, the important factor for PYY to exert its affects on food intake appears to be that the animals have to be properly conditioned to the experimental environment prior to the start of the experiment [11 • ].
Recently, it has been found that exogenous administration of PYY 3-36 reduces appetite to a similar degree in obese volunteers and normal weight controls [44 •• ] . This paper also showed that obese individuals had lower circulating PYY than normal weight controls. This suggests that changes in the release of circulating gut hormones may contribute towards the pathophysiology of obesity.
PP binds with greatest affinity to Y4 and Y5 receptors. It is found predominantly in the endocrine pancreas, and its release is stimulated by food intake, with post-prandial plasma levels proportional to caloric intake.
Peripheral administration of PP suppresses food intake and gastric emptying in rodents [45 • ,46 • ]. In contrast, central administration of PP increases food intake and gastric emptying. It has been suggested that the effect of PP on food intake may therefore be secondary to the effects on gastric emptying [47] . However, intravenous infusion of PP has also been shown to reduce food intake in humans without affecting gastric emptying [48 • ]. The inimical effects of central and peripheral PP may represent the activation of different receptor subtypes. Peripheral PP has also recently been shown to increase hypothalamic NPY expression and also increase oxygen consumption and stimulate the sympathetic nervous system, suggesting it may increase energy expenditure [45 • ].
Glucagon-like peptide 1 and oxyntomodulin
Glucagon-like peptide-1 (7-36) amide (GLP-1) and oxyntomodulin (OXM) are produced by post-translational processing of the preproglucagon gene in the CNS and the intestine and colon. Both peptides are released into the circulation in response to nutrient intake and appear to function as satiety signals.
GLP-1 receptors are found in the brainstem, ARC and PVN, in addition to various peripheral tissues. Like GLP-1, OXM also inhibits or reduces food intake when administered centrally or peripherally [49 • ,50 • ,51 • ]. As with GLP-1, these anorectic effects can be blocked by the GLP-1 receptor antagonist, exendin (9-39) [52] , suggesting that OXM also signals via the GLP-1 receptor. However, OXM and GLP-1 are equally efficacious at reducing food intake, yet the affinity of OXM for the GLP-1 receptor is much lower than that of GLP-1 [53] . It is possible that another as yet unknown OXM receptor exists, which has strong similarities to the GLP-1 receptor.
Peripheral administration of OXM activates neurons in the ARC, and intra-ARC administration of exendin (9-39) blocks the anorectic actions of peripheral OXM but not GLP-1, suggesting that OXM and GLP-1 may reduce food intake by different pathways. In addition, chronic peripheral administration of OXM causes a reduction in weight gain in rats [50 • ]. Peripheral OXM may reduce food intake via the ARC, while GLP-1 may act on appetite through the area postrema in the brain stem [54 • ].
While intravenous infusion of GLP-1 in man has a significant effect on appetite at physiologic concentrations, only pathophysiological levels of circulating OXM have been demonstrated to reduce calorie intake [19 • ,55 • ]. Further work is required to elucidate the physiologic significance of OXM in human appetite. Interestingly, both human OXM infusion and rat intraperitoneal injection reduce plasma ghrelin levels; this might be responsible for the observed reduction in appetite [50 • ,55 • ].
Conclusion
The neuroendocrine regulation of food intake is complex and involves the brain receiving both neuronal and hormonal inputs. Great progress has been made to increase understanding of these systems and a full understanding of central regulation of food intake is likely to come within a few years. Gut hormones have surprisingly been found to be important in appetite regulation. Targeting the gut hormones involved with appetite control will allow rational development of new therapies that may help to reverse the ongoing acceleration of the current obesity epidemic and reduce morbidity and mortality.
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